Search

Your search keyword '"Bozic, Boris"' showing total 17 results
Start Over Author "Bozic, Boris"
17 results on '"Bozic, Boris"'

3. Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant‐ineligible patients with newly diagnosed multiple myeloma

Author

Ludwig, Heinz, primary, Melchardt, Thomas, additional, Sormann, Siegfried, additional, Schreder, Martin, additional, Andel, Johannes, additional, Hartmann, Bernd, additional, Tinchon, Christoph, additional, Zojer, Niklas, additional, Gunsilius, Eberhard, additional, Podar, Klaus, additional, Egle, Alexander, additional, Willenbacher, Wolfgang, additional, Wöll, Ewald, additional, Ruckser, Reinhard, additional, Bozic, Boris, additional, Krauth, Maria‐Theresa, additional, Petzer, Andreas, additional, Schmitt, Clemens, additional, Machherndl‐Spandl, Sigrid, additional, Agis, Hermine, additional, Fillitz, Michael, additional, Wang, Song‐Yau, additional, Zabernigg, August, additional, Knop, Stefan, additional, Paiva, Bruno, additional, and Greil, Richard, additional

Published
2024
Full Text
View/download PDF

4. QoL during KTd or KRd induction followed by K maintenance or observation in transplant noneligible patients with newly diagnosed multiple myeloma: Longitudinal and cross‐sectional analysis of the randomized AGMT 02 study.

Author

Ludwig, Heinz, Melchardt, Thomas, Schweitzer, Ilvy, Sormann, Siegfried, Schreder, Martin, Andel, Johannes, Hartmann, Bernd, Zojer, Niklas, Schöffmann, Laurenz, Gunsilius, Eberhard, Podar, Klaus, Egle, Alexander, Willenbacher, Wolfgang, Wöll, Ewald, Ruckser, Reinhard, Bozic, Boris, Krauth, Maria‐Theresa, Petzer, Andreas, Schmitt, Clemens, and Machherndl‐Spandl, Sigrid

Published
2024
Full Text
View/download PDF

5. P943: OUTCOME ANALYSIS BY CYTOGENETIC RISK GROUP AFTER RANDOMIZATION TO KRD OR KTD FOLLOWED BY K MAINTENANCE OR CONTROL IN PATIENTS WITH NTE NDMM (AGMT MM-02)

Author

Ludwig, Heinz, primary, Melchardt, Thomas, additional, Sormann, Siegfried, additional, Schreder, Martin, additional, Andel, Johannes, additional, Hartmann, Bernd, additional, Tinchon, Christoph, additional, Zojer, Niklas, additional, Gunsilius, Eberhard, additional, Podar, Klaus, additional, Egle, Alexander, additional, Willenbacher, Wolfgang, additional, Woell, Ewald, additional, Ruckser, Reinhard, additional, Bozic, Boris, additional, Theresa Krauth, Maria, additional, Petzer, Andreas, additional, Schmitt, Clemens A., additional, Machherndl-Spandl, Sigrid, additional, Agis, Hermine, additional, Fillitz, Michael, additional, Wang, Song-Yau, additional, Knop, Stefan, additional, Paiva, Bruno, additional, and Greil, Richard, additional

Published
2023
Full Text
View/download PDF

8. Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant Non-Eligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial)

Author

Ludwig, Heinz, primary, Melchardt, Thomas, additional, Sormann, Siegfried, additional, Zojer, Niklas, additional, Andel, Johannes, additional, Hartmann, Bernd L., additional, Tinchon, Christoph, additional, Gunsilius, Eberhard, additional, Podar, Klaus, additional, Egle, Alexander, additional, Willenbacher, Wolfgang, additional, Wöll, Ewald, additional, Schreder, Martin, additional, Ruckser, Reinhard, additional, Bozic, Boris, additional, Krauth, Maria-Theresa, additional, Petzer, Andreas, additional, Schmitt, Clemens A., additional, Machherndl-Spandl, Sigrid, additional, Agis, Hermine, additional, Fillitz, Michael, additional, Wang, Song-Yau, additional, Knop, Stefan, additional, Kainz, Sarah, additional, Paiva, Bruno, additional, and Greil, Richard, additional

Published
2022
Full Text
View/download PDF

9. Gastrointestinale Stromatumoren (GIST).

Author

Jaros, David, Bozic, Boris, and Sebesta, Christian

Abstract

Copyright of Wiener Medizinische Wochenschrift is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2023
Full Text
View/download PDF

10. Composition of the Immune Environment at Baseline Correlates with Time to Response and Treatment Outcome in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (MM) Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Observation (AGMT_MM 02 Study)

Author

Manrique, Irene, primary, Greil, Richard, additional, Andel, Johannes, additional, Sormann, Siegfried, additional, Hartmann, Bernd L., additional, Podar, Klaus, additional, Egle, Alexander, additional, Petzer, Andreas, additional, Zojer, Niklas, additional, Gunsilius, Eberhard, additional, Ruckser, Reinhard, additional, Bozic, Boris, additional, Schmitt, Clemens A., additional, Machherndl-Spandl, Sigrid, additional, Agis, Hermine, additional, Schreder, Martin, additional, Wang, Song-Yau, additional, Willenbacher, Wolfgang, additional, Krauth, Maria-Theresa, additional, Tinchon, Christoph, additional, Fillitz, Michael, additional, Melchardt, Thomas, additional, Knop, Stefan, additional, Paiva, Bruno, additional, and Ludwig, Heinz, additional

Published
2021
Full Text
View/download PDF

12. Quality of Life in Newly Diagnosed Patients with Multiple Myeloma Randomized to Either Krd or Ktd Induction Therapy Followed By Carfilzomib Maintenance or Control (AGMT MM 02 trial)

Author

Ludwig, Heinz, Melchardt, Thomas, Andel, Johannes, Gunsilius, Eberhard, Sormann, Siegfried, Hinke, Axel, Hartmann, Bernd L., Podar, Klaus, Willenbacher, Wolfgang, Egle, Alexander, Petzer, Andreas, Zojer, Niklas, Wöll, Ewald, Ruckser, Reinhard, Bozic, Boris, Schmitt, Clemens A., Machherndl-Spandl, Sigrid, Krauth, Maria-Theresa, Schreder, Martin, Agis, Hermine, Tinchon, Christoph, Fillitz, Michael, and Greil, Richard

Published
2020
Full Text
View/download PDF

13. Immunophenotyping of Baseline Bone Marrow Reveals a Specific Pattern of Immune Cells Associated with Greater Depth and Sustained Response in Newly Diagnosed Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Control (AGMT MM 02 Study)

Author

Manrique, Irene, primary, Greil, Richard, additional, Andel, Johannes, additional, Sormann, Siegfried, additional, Hartmann, Bernd L., additional, Podar, Klaus, additional, Egle, Alexander, additional, Petzer, Andreas, additional, Zojer, Niklas, additional, Ruckser, Reinhard, additional, Bozic, Boris, additional, Schmitt, Clemens A., additional, Machherndl-Spandl, Sigrid, additional, Agis, Hermine, additional, Schreder, Martin, additional, Krauth, Maria-Theresa, additional, Tinchon, Christoph, additional, Fillitz, Michael, additional, Melchardt, Thomas, additional, Paiva, Bruno, additional, and Ludwig, Heinz, additional

Published
2020
Full Text
View/download PDF

14. Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2 Twice Weekly Cycles) Followed By Carfilzomib Maintenance Vs. Control in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02)

Author

Ludwig, Heinz, primary, Sormann, Siegfried, primary, Zojer, Niklas, primary, Andel, Johannes, primary, Hartmann, Bernd L., primary, Tinchon, Christoph, primary, Gunsilius, Eberhard, primary, Podar, Klaus, primary, Egle, Alexander, primary, Willenbacher, Wolfgang, primary, Wöll, Ewald, primary, Ruckser, Reinhard, primary, Bozic, Boris, primary, Krauth, Maria-Theresa, primary, Petzer, Andreas, primary, Schmitt, Clemens A., primary, Machherndl-Spandl, Sigrid, primary, Agis, Hermine, primary, Paiva, Bruno, primary, and Greil, Richard, primary

Published
2019
Full Text
View/download PDF

16. Alcohol-Related Road Traffic Accidents Before and After the Passing of the Road Traffic Safety Act in Croatia.

Author

Missoni, Eduard, Bozic, Boris, and Missoni, Ivan

Subjects
DRUNK driving, TRAFFIC accidents, PHYSIOLOGICAL effects of alcohol, TRAFFIC safety, POLICE reports, EPIDEMIOLOGY
Abstract

Copyright of Collegium Antropologicum is the property of Croatian Anthropological Society and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2012

17. [Gastrointestinal stromal tumors (GIST)].

Author

Jaros D, Bozic B, and Sebesta C

Subjects
Humans, Aged, Imatinib Mesylate therapeutic use, Receptor, Platelet-Derived Growth Factor alpha genetics, Receptor, Platelet-Derived Growth Factor alpha therapeutic use, Protein Kinase Inhibitors therapeutic use, Mutation, Proto-Oncogene Proteins c-kit genetics, Proto-Oncogene Proteins c-kit therapeutic use, Gastrointestinal Stromal Tumors diagnosis, Gastrointestinal Stromal Tumors drug therapy, Gastrointestinal Stromal Tumors genetics, Antineoplastic Agents therapeutic use, Gastrointestinal Neoplasms diagnosis, Gastrointestinal Neoplasms drug therapy, Gastrointestinal Neoplasms genetics
Abstract

Gastrointestinal stromal tumors (GIST) are rare tumors with a varying malignancy potential, most frequently located in the stomach and the small intestine. The median age at diagnosis is around 65 years. Standard treatment of localized disease is complete surgical resection. A GIST is generally resistant to conventional chemotherapy. Most GISTs harbor tyrosine kinase activating mutations in either the KIT or PDGFRA proto-oncogene. The standard treatment of locally advanced and metastatic GIST with such mutations is the tyrosine kinase inhibitor imatinib. In cases of progressive disease after successive treatment with imatinib, sunitinib, and regorafenib, a fourth-line therapy with ripretinib was recently approved. Approved in 2020, avapritinib is the first effective targeted therapy for advanced stage GIST harboring an imatinib-resistant PDGFRA D842V mutation., (© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, ein Teil von Springer Nature.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results